In conclusion, both HSP90 protein overexpression and lower PTEN expression were poor prognostic factors, which implied that HSP90 inhibitors and PI3K/mTOR inhibitors are potential therapeutic agents in CCA. This evidence concerns the gene PTEN and cholangiocarcinoma.